We are live on ! Find out more
MREO

Mereo BioPharma
MREO

64 hedge funds and large institutions have $182M invested in Mereo BioPharma in 2023 Q4 according to their latest regulatory filings, with 17 funds opening new positions, 19 increasing their positions, 13 reducing their positions, and 9 closing their positions.

New
Increased
Maintained
Reduced
Closed

1,970% more call options, than puts

Call options by funds: $2.21M | Put options by funds: $107K

101% more capital invested

Capital invested by funds: $90.4M → $182M (+$91.2M)

89% more first-time investments, than exits

New positions opened: 17 | Existing positions closed: 9

46% more repeat investments, than reductions

Existing positions increased: 19 | Existing positions reduced: 13

14% more funds holding

Funds holding: 56 → 64 (+8)

1.15% more ownership

Funds ownership: 10.06% → 11.21% (+1.2%)

Holders
64
Holders Change
+8
Holders Change %
+14.29%
% of All Funds
0.93%
Holding in Top 10
1
Holding in Top 10 Change
+1
Holding in Top 10 Change %
% of All Funds
0.01%
New
17
Increased
19
Reduced
13
Closed
9
Calls
$2.21M
Puts
$107K
Net Calls
+$2.11M
Net Calls Change
+$1.45M

Top Buyers

Rank Fund Capital Flow
1
MP
Mangrove Partners
Connecticut
+$6.16M
2
RCMNY
Rubric Capital Management (New York)
New York
+$3.7M
3
Adage Capital Partners
Adage Capital Partners
Massachusetts
+$3.54M
4
Aberdeen Group
Aberdeen Group
United Kingdom
+$2.97M
5
Alkeon Capital Management
Alkeon Capital Management
New York
+$956K

Top Sellers

Rank Fund Capital Flow
1
Citadel Advisors
Citadel Advisors
Florida
-$3.67M
2
JGC
J. Goldman & Co
New York
-$542K
3
FAM
Formidable Asset Management
Ohio
-$428K
4
DCM
DAFNA Capital Management
California
-$351K
5
JP Morgan Chase
JP Morgan Chase
New York
-$217K
Name Holding Trade Value Shares
Change 		Change in
Stake
UBS Group
51
UBS Group
Switzerland
$6.5K +$5.38K +2,813 New
Northwestern Mutual Wealth Management
52
Northwestern Mutual Wealth Management
Wisconsin
$4.16K +$3.44K +1,800 New
AF
53
Allworth Financial
California
$3.46K – – –
SIA
54
Sit Investment Associates
Minnesota
$2K – – –
SWM
55
Spire Wealth Management
Virginia
$789 +$478 +250 New
NECFA
56
New England Capital Financial Advisors
Connecticut
$693 – – –
Bank of America
57
Bank of America
North Carolina
$638 -$17.1K -8,942 -97%
Wells Fargo
58
Wells Fargo
California
$530 – – –
HCM
59
Highlander Capital Management
New Jersey
$293 – – –
PMFA
60
Plante Moran Financial Advisors
Michigan
$111 – – –
Barclays
61
Barclays
United Kingdom
$88 -$73 -38 -50%
US Bancorp
62
US Bancorp
Minnesota
$30 – – –
BNP Paribas Financial Markets
63
BNP Paribas Financial Markets
France
$7 – – –
IC
64
Ikarian Capital
Texas
– -$191K -591,676 Closed
FAM
65
Formidable Asset Management
Ohio
– -$428K -331,914 Closed
BFM
66
Boothbay Fund Management
New York
– -$156K -120,584 Closed
PFMU
67
Privium Fund Management (UK)
United Kingdom
– -$32.4K -24,726 Closed
Jane Street
68
Jane Street
New York
– -$22.3K -17,285 Closed
Creative Planning
69
Creative Planning
Kansas
– -$20.4K -15,820 Closed
ACP
70
Arcus Capital Partners
Georgia
– -$19.4K -15,000 Closed
OC
71
Oppenheimer & Co
New York
– -$18.1K -14,000 Closed
XT
72
XTX Topco
Cayman Islands
– -$14.6K -11,313 Closed
Royal Bank of Canada
73
Royal Bank of Canada
Ontario, Canada
– +$109 +57 New
1 2
3

MREO Hedge Fund Activity: Q4 2023 in Review

64 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in Mereo BioPharma (MREO) for Q4 2023, worth a combined $182M — up 101% from $90.4M a quarter earlier.

Buyers outnumbered sellers: 17 funds opened new MREO positions and 9 closed out — a net gain of 8 holders — while 19 added to existing stakes and 13 trimmed.

The largest buyer was Mangrove Partners, adding an estimated $6.16M. The largest seller was Citadel Advisors, cutting an estimated $3.67M.

  • 64 institutional investors held Mereo BioPharma (MREO) as of Q4 2023, up from 56 in Q3 2023.
  • Funds reported $182M of Mereo BioPharma stock for Q4 2023, up 101% quarter-over-quarter.
  • 17 funds opened new Mereo BioPharma positions in Q4 2023 and 9 closed out, a net change of +8 holders.
  • The largest Mereo BioPharma buyer in Q4 2023 was Mangrove Partners, an estimated $6.16M added.
  • The largest Mereo BioPharma seller in Q4 2023 was Citadel Advisors, an estimated $3.67M sold.

Based on aggregated 13F filings for Q4 2023.